New government data reveal that cannabis overdose deaths accounted for more than one in five of all unintentional and undetermined overdose deaths recorded in the United States between January 2021 and June 2025, with the youngest age group hit hardest of all.

How Common Are Cannabis Overdose Deaths?

The findings come from the Centers for Disease Control and Prevention’s State Unintentional Drug Overdose Reporting System, which tracked 209,166 overdose deaths across 31 states and the District of Columbia during that period. Cannabis turned up in the toxicology reports of 43,880 of those deaths, a rate of 21.0% that barely moved from year to year.

Teenagers Stand Out From Every Other Age Group

Break the numbers down by age, though, and a very different picture appears. Among decedents aged 12 to 17, cannabis overdose deaths made up 42.7% of the total, by far the highest share of any age group. That figure dipped from 49.2% in 2021 to 35.9% in 2024, before climbing back up to 44.6% in the first half of 2025.

Adults aged 50 and older sat at the opposite end of the scale, with cannabis detected in 16.7% of their overdose deaths, though even that figure crept upwards, from 14.8% in 2021 to 18.1% by mid 2025. That gradual climb in marijuana overdose deaths among older adults tells a much steadier story than the sharp swings seen among teenagers.

What makes the teenage figures stand out is that they run against the general trend of use. Survey data cited in the report show that past year cannabis use among adolescents has actually held steady or dipped slightly in recent years, and remains lower than among adults. Yet somehow, marijuana overdose deaths are proportionally far more common in this age group than in any other.

Cannabis Alone Rarely Kills

Cannabis was recorded as the actual cause of death in only 0.8% of cases, 1,687 out of the full total, and just nine deaths involved cannabis with no other substance present. The researchers behind the report are blunt about it: cannabis rarely kills on its own. What the toxicology results point to instead is polysubstance use, cannabis turning up alongside drugs that are far more dangerous.

Among all deaths where cannabis was detected, 73.5% also involved illegally manufactured fentanyl, and 60.4% involved stimulants such as cocaine or methamphetamine. Those figures climbed even higher for adolescents, with fentanyl present in 88.6% of teenage cases and stimulants in 69.0%. Cannabis overdose deaths among teenagers, then, are almost never about cannabis by itself. They’re markers of much riskier drug combinations.

The true scale may be larger still. Because cannabis is so rarely the actual cause of death, screening for cannabinoids isn’t done consistently in every case, so cannabis use among overdose victims is probably undercounted.

What the Findings Mean for Prevention

An estimated 64.2 million Americans aged 12 and older reported using cannabis in 2024. Against that number, cannabis turning up in one in five overdose deaths, and in more than four in ten among adolescents, is worth sitting with. Cannabis itself probably isn’t driving these fatalities. Its presence is more of a clue to what else a young person has likely been exposed to.

The report’s authors treat adolescence as a critical window for stepping in early, before cannabis use opens the door to riskier polysubstance patterns later on. They point to community based programmes, including the CDC’s Drug Free Communities Support Program and the Evidence Based Strategies to Prevent Youth Substance Use initiative known as ENGAGE, as ways to give young people, and the adults around them, the tools to change course. Getting that support in place early, the data suggest, could shape not just how teenagers fare now, but the substance use patterns they carry into adulthood.

Cannabis overdose deaths, or marijuana overdose deaths as this latest CDC snapshot also calls them, may still be relatively rare in isolation. But taken together, the figures are a useful warning sign, and for teenagers in particular, one that deserves far more attention than it currently gets.

Source: thedrugreport